surmount-1 tirzepatide obesity nejm 2022 weight loss percent 📊 Semaglutide 2.4mg: −13.7% (SURMOUNT-5 head-to-head), 📊 15mg: −20.2% weight loss (same trial, 2025), 📊 Retatrutide 12mg: −28.7% weight loss (TRIUMPH-4, Phase 3, Dec Semaglutide vs. Tirzepatide: Which Weight

In preclinical models , this contributes to increased metabolic activity and reduced fat accumulation

In addition, prevention and treatment of hypoglycemia with excessive carbohydrates also contribute to weight gain

A comprehensive medical evaluation may include: a detailed medical history discussion of when symptoms began previous injuries or surgery activity level and exercise habits physical examination imaging studies such as X-rays or MRI when clinically appropriate This information helps determine not only the cause of knee pain but also whether regenerative therapies, including peptides, may be appropriate as part of a broader treatment plan

clinicaltrials.gov/study/NCT03811561 27

Efficacy and safety of once-weekly tirzepatide for weight management compared to placebo: An updated systematic review and meta-analysis including the latest SURMOUNT-2 trial - Springer Nature Clinical Consequences of Delayed Gastric Emptying With GLP-1 Receptor Agonists and Tirzepatide - The Journal of Clinical Endocrinology & Metabolism Tirzepatide is an imbalanced and biased dual GIP and GLP-1 receptor agonist - JCI Insight Fibre intake for optimal health: how can healthcare professionals support people to reach dietary recommendations